Free Trial
TSE:ATE

Antibe Therapeutics (ATE) Stock Price, News & Analysis

Antibe Therapeutics logo

About Antibe Therapeutics Stock (TSE:ATE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
167,044 shs
Average Volume
135,475 shs
Market Capitalization
C$15.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATE Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc ATE
Antibe Announces Early Warrant Exercise Incentive Program
See More Headlines

ATE Stock Analysis - Frequently Asked Questions

Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Antibe Therapeutics investors own include Resverlogix (RVX), Royal Bank of Canada (RY), Tesla (TSLA), Unrivaled Brands (TRTC), Baytex Energy (BTE), Enbridge (ENB) and NVIDIA (NVDA).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:ATE
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
C($0.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$18.24 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-52.72%
Return on Assets
-19.13%

Debt

Debt-to-Equity Ratio
0.29
Current Ratio
10.06
Quick Ratio
9.58

Sales & Book Value

Annual Sales
C$9.71 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
0.61
Book Value
C$0.49 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
53,010,000
Free Float
N/A
Market Cap
C$15.64 million
Optionable
Not Optionable
Beta
0.19
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (TSE:ATE) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners